Firalis产品代理
Firalis产品代理
Firalis 通过生物标志物的发现、开发和监管资格创造新的价值，并将基于生物标志物的诊断产品推向市场。凭借在该领域的全面专业知识，Firalis 开发诊断试剂盒并提供广泛的生物标志物服务；改善治疗决策以及疾病结果和患者舒适度，最终显着降低医疗保健成本。
Firalis 的活动主要但非排他性地涉及炎症性疾病的生物标志物，如动脉粥样硬化、类风湿性关节炎、罕见/孤儿疾病如系统性或自身免疫性血管炎。我们活动的主要部分涵盖药物引起的器官损伤，特别是肾脏、肝脏和脉管系统，作为主要的药物靶点。
自 2008 年以来，Firalis 在其独特的临床医生和卓越临床中心网络中获得了其在转化生物标志物方面的开创性领导地位，这要归功于它协调的许多研发联盟，包括来自欧洲学术界（主要是大学医院）、大制药和其他具有互补专业知识的中小企业。对于众多研发项目，Firalis 已获得研究和创业奖以及重要的研究资助，这使我们能够进行一些有史以来最大的临床生物标志物研究。
在 Firalis，我们专门投资具有最高成功潜力的项目，不断将新产品商业化，并致力于推出我们自己的高价值体外诊断试剂盒。
FIRALIS is a biotechnology company located in the very heart of BioValley, on the true triple border of FR-DE-CH, only a few minutes walking distance to Basel, the pharmaceutical capital of Europe.
Firalis creates novel values via biomarker discovery, development and regulatory qualification and brings to market biomarker-based diagnostic products. With a comprehensive expertise in the field, Firalis develops diagnostic kits and provides an extensive range of biomarker services; to improve therapeutic decisions as well as disease outcomes and patient comfort, finally to reduce healthcare costs at remarkable extents.
Activities of Firalis mainly but non-exclusively involve biomarkers of inflammatory disorders such as atherosclerosis, rheumatoid arthritis, rare/orphan diseases
such as systemic or autoimmune vasculitis. A major part of our activities cover drug-induced organ injuries in particularly kidney, liver and vasculature, as major drug targets.
Firalis acquired its pioneering leadership in translational biomarkers to its unique network of clinicians and clinical centers of excellence that it built step by step, since 2008, thanks to many R&D consortia it coordinated, consisting partners from the European Academia (mostly University Hospitals), Big Pharma and other SME with complementary know-how. For numerous of its R&D projects, Firalis has been awarded with research and entrepreneurship awards as well as significant research grants which allowed us to conduct some of the largest clinical biomarker studies ever.
At Firalis, we exclusively invest on projects with highest potential of success, commercialize constantly new products, and target to launch a high-value in-vitro diagnostic kit of our own.
